GordianTec Pty Ltd
Yuuwa Capital has recently completed an investment in GordianTec Pty Ltd. This company is founded on ground breaking research into the genetics of complex diseases conducted by Professor Grant Morahan at the Western Australian Institute for Medical Research. The company’s name stems from the legend of the Gordian Knot which is often used as a metaphor for an intractable problem solved by a bold stroke (“cutting the Gordian knot”).
Further details about this investment will be provided in due course.
OzSonotek Pty Ltd
OzSonotek’s first product is a next generation needle for phacoemulsification cataract surgery. The new needle provides significant surgical performance benefits over existing technologies in a market that completes more than 10 million procedures a year.
Yuuwa Capital Investment Directors James Williams and Liddy McCall have direct experience taking ophthalmic devices to market, and will complement the board and management’s expertise to allow this first product to progress rapidly to market.
The Press Announcement is linked here: Yuuwa OzSonotek Agreement Press Release
Adalta Pty Ltd
AdAlta uses its proprietary antibody libraries, derived from shark antibodies and human proteins with shark antibody properties (i-bodies), to develop new therapeutics targeting cancer. AdAlta’s next generation antibodies have a unique structure with the potential to bind new therapeutic targets that are difficult to address using traditional antibodies. They are also smaller than conventional antibodies making them easier and cheaper to manufacture. Visit www.adalta.com.au for more information.
Yuuwa is looking forward to supporting AdAlta in demonstrating the efficacy of its next generation antibody technology and the licensing of the libraries to pharmaceutical companies.
The Press Announcement is linked here: Yuuwa AdAlta Agreement Press Release